{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:08:23Z","timestamp":1782698903280,"version":"3.54.5"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T00:00:00Z","timestamp":1338422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The efficacy of a novel vaccine against influenza virus A (<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1) in patients with hematologic malignancies is largely unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively evaluated the humoral and cellular immune responses after one injection of monovalent adjuvanted 2009 <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1 vaccine in 47 adults with hematologic malignancies and 77 controls by hemagglutination\u2010inhibition assay and flow\u2010cytometry analysis on day 0, 28, 50, and 90.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>On day 28 postvaccination, patients had lower seroprotection (95.2% vs. 75.2%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) and seroconversion (88.7% vs. 51.1%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) rates, as well as geometric mean titer (<jats:styled-content style=\"fixed-case\">GMT<\/jats:styled-content>; 256 vs. 134, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), relative to controls. Response to vaccination varied according to the evaluated time point and the patient status: Patients not receiving chemotherapy had seroprotection and <jats:styled-content style=\"fixed-case\">GMT<\/jats:styled-content>s similar to controls in all time points, while patients receiving chemotherapy or allogeneic hematopoietic stem cell transplant (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) had lower seroprotection and seroconversion levels than controls on day 28 and 50. <jats:styled-content style=\"fixed-case\">EMEA<\/jats:styled-content> cutoffs for efficacy were reached from day 28 by patients in follow\u2010up or under treatment and only from day 90 by those with <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>, especially if still under immunosuppressants. Patients treated with immunomodulatory drugs had higher antibody responses in terms of seroprotection and <jats:styled-content style=\"fixed-case\">GMT<\/jats:styled-content>s. <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010 and <jats:styled-content style=\"fixed-case\">NK<\/jats:styled-content> cell\u2010mediated responses mounted from day 50 and did not differ between patients and controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>According to <jats:styled-content style=\"fixed-case\">EMEA<\/jats:styled-content> recommendation, <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1 vaccination strategy was effective at protecting most of the hematologic patients, but needed to be improved in those more immunocompromised.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1600-0609.2012.01793.x","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T14:10:26Z","timestamp":1335535826000},"page":"111-119","source":"Crossref","is-referenced-by-count":17,"title":["Long\u2010term patterns of humoral and cellular response after vaccination against influenza A (<scp>H<\/scp>1<scp>N<\/scp>1) in patients with hematologic malignancies"],"prefix":"10.1111","volume":"89","author":[{"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spina","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Carniti","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Anselmi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sanit\u00e0 Pubblica, Microbiologia Virologia dell'Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lucini","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vendramin","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pregliasco","sequence":"additional","affiliation":[{"name":"Dipartimento di Sanit\u00e0 Pubblica, Microbiologia Virologia dell'Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit Fondazione IRCCS Istituto Nazionale dei Tumori  Milan Italy"},{"name":"Universit\u00e0 degli Studi di Milano  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70175-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-976494"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000232560.22098.4e"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11777102"},{"key":"e_1_2_6_6_1","volume-title":"H1N1 Flu: International Situation Update","author":"Center for Disease Control and Prevention","year":"2009"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1000449"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1496"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1583"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906695"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908535"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907413"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907650"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.032664"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.10.002"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.024"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/597401"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.07.017"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2062"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227934"},{"key":"e_1_2_6_21_1","volume-title":"Note for Guidance on Harmonisation of Requirements for influenza Vaccines","author":"Committee for Proprietary Meicinal Products","year":"1996"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.105"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6908"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-5-552"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705159"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.3.4.214"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.100"},{"key":"e_1_2_6_28_1","volume-title":"Note for Guidance on Harmonization of Requirements for Influenza Vaccines","author":"EMEA","year":"1997"},{"key":"e_1_2_6_29_1","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay AG","year":"2008","journal-title":"J Clin Invest"},{"key":"e_1_2_6_30_1","article-title":"Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines","volume":"114","author":"Noonan KA","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/313663"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.053"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05582.x"},{"key":"e_1_2_6_34_1","first-page":"1","article-title":"Antibody response to a two\u2010dose regimen of influenza vaccine in allogeneic T cell\u2010depleted and autologous BMT recipients","volume":"11","author":"Engelhard D","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.004"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040386"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.264"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.080"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00357-07"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2012.01793.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2012.01793.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:56:25Z","timestamp":1700600185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2012.01793.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1600-0609.2012.01793.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01793.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]}}}